Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02829827
Recruitment Status : Terminated (After reviewing the feasibility and projected completion date of the study, UCB has made the decision to stop the study)
First Posted : July 12, 2016
Last Update Posted : September 17, 2019
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

Brief Summary:
The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms

Condition or disease Intervention/treatment Phase
Infantile Spasms (IS) Drug: Radiprodil Phase 2

Detailed Description:

The study is divided into 3 parts:

Part A - exploratory, Part B - confirmatory, Part C - open label extension


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Adaptive Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Radiprodil in Subjects With Drug-resistant Infantile Spasms
Actual Study Start Date : December 4, 2017
Actual Primary Completion Date : October 2, 2018
Actual Study Completion Date : October 2, 2018


Arm Intervention/treatment
Experimental: Radiprodil
Each subject will enter an individualized dose titration schedule.
Drug: Radiprodil
Radiprodil at individualized doses.




Primary Outcome Measures :
  1. Percentage of subjects with clinical response on Day 14 of treatment with the maintenance dose of radiprodil [ Time Frame: Day 14, counting from the first day of radiprodil at maintenance dose ]
    Clinical response is defined as no spasms on Day 14 of treatment with the maintenance dose of radiprodil. This is the primary efficacy variable for Part A.

  2. Estimates of exposure generated from a population-Pharmacokinetic modelling [ Time Frame: Samples will be taken at baseline (time during Day -14 to -1 prior to dosing) and 3, 4, 5 & 12hr after the 1st dose on Day 1 of radiprodil low, mid & high dose. Blood samples will be taken at same timepoints after 1st dose on Day 2 of radiprodil low dose ]
    This is a primary variable for Part A.

  3. Percentage of subjects with electro-clinical response on Day 14 of treatment with the maintenance dose of radiprodil [ Time Frame: Day 14, counting from the first day of radiprodil at maintenance dose ]
    Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is the primary efficacy variable for Part B.

  4. Incidence of Adverse Events (AEs) during the study [ Time Frame: From Baseline (Day -1) to the end of the Post-treatment Period (28 days post last dosing) ]
    An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage. This is a primary variable for all parts.


Secondary Outcome Measures :
  1. Percentage of subjects with electro-clinical response on Day 14 of treatment with the maintenance dose of radiprodil [ Time Frame: Day 14, counting from the first day of radiprodil at maintenance dose ]
    Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is the secondary efficacy variable for Part A.

  2. Percentage of subjects with clinical response on Day 14 of treatment with the maintenance dose of radiprodil [ Time Frame: Day 14, counting from Day 14 of treatment with the maintenance dose of radiprodil ]
    Clinical response is defined as no spasms on Day 14 of treatment with the maintenance dose of radiprodil. This is the secondary efficacy variable for Part B.

  3. Estimates of exposure generated from a population-Pharmacokinetic modelling [ Time Frame: Pharmacokinetic samples will be collected on Day 1 of radiprodil low dose, mid dose and high dose. Additionally, blood samples will be taken after 1st dose on Day 2 of radiprodil low dose. ]
    This is a secondary variable for Part B.

  4. Time to cessation of spasms [ Time Frame: During the first 14 days of treatment with radiprodil ]
    Time to cessation of spasms for clinical responders on Day 14 of treatment with the maintenance dose of radiprodol. This is a secondary efficacy variable for parts A and B.

  5. Percentage of responders with clinical relapse [ Time Frame: 12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil ]
    The percentage of clinical responders on Day 14 of treatment with the maintenance dose of radiprodil with clinical relapse within 12 months. This is a secondary efficacy variable for parts A and B.

  6. Time to clinical relapse from the day of spasm cessation [ Time Frame: From day of spasms cessation up to 42 months of age ]
    This is a secondary efficacy variable for parts A and B.

  7. Percentage of electro-clinical responders with electro-clinical relapse [ Time Frame: 12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil ]
    The percentage of electro-clinical responders on Day 14 of treatment with the maintenance dose of radiprodil with electro-clinical relapse within 12 months. This is a secondary efficacy variable for parts A and B.

  8. Time to electro-clinical relapse from the day of spasm cessation [ Time Frame: From day of spasms cessation up to 42 months of age ]
    This is a secondary efficacy variable for parts A and B.

  9. Percentage of subjects with extended clinical response [ Time Frame: 28 days, counting from Day 14 (inclusive) of treatment with the maintenance dose of radiprodil ]
    Extended clinical response is defined as no spasms for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for parts A and B.

  10. Percentage of subjects with extended electro-clinical response [ Time Frame: 28 days, counting from Day 14 (inclusive) of treatment with the maintenance dose of radiprodil ]
    Extended electro-clinical response is defined as no spasms and resolution of hypsarrythmia for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for parts A and B.

  11. Percentage of subjects with extended clinical response to each additional treatment cycle on Day 14 of treatment with the maintenance dose of radiprodil [ Time Frame: 28 days, counting from Day 14 (inclusive) of maintenance dose ]
    Extended clinical response is defined as no spasms for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for part C.

  12. Number of treatment cycles per subject [ Time Frame: During Part C (Day -1 to Day 28 of the Maintenance Period) ]
    This is a secondary variable for Part C.

  13. Percentage of subjects with electro-clinical response to each additional treatment cycle on Day 14 of treatment with the maintenance dose of radiprodil [ Time Frame: Day 14, counting from the first day of maintenance dose ]
    Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for Part C.

  14. Time to clinical relapse from the first day of no witnessed spasms for each treatment cycle [ Time Frame: From day of no witnessed spasms up to 42 months of age ]
    This is a secondary efficacy variable for part C.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 14 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Part A and B:

  • Subject is male or female between 2 and 14 months of age
  • The diagnosis of infantile spasms (IS)
  • Subject has drug-resistant IS

Part C:

  • Subject participated in EP0078 Part A and received 2 radiprodil treatment cycles
  • Subject experienced a relapse of spasms during the down taper or within 5 half-lives (3 days) discontinuation of radiprodil treatment in Cycle 2 of Part A
  • Electroencephalogram (EEG) on baseline Part C is compatible with the diagnosis of infantile spasms

Exclusion Criteria:

Part A and B:

  • More than 6 months have passed since the diagnosis of Infantile Spasms (IS)
  • Current treatment with cannabinoids
  • Subject has hematocrit greater than 60
  • Subject has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has a history or current condition predisposing to respiratory dysfunction
  • Current treatment with felbamate
  • Current treatment with perampanel
  • Ketogenic diet
  • Clinically significant lab abnormalities
  • Clinically significant abnormality on ECG that, in the opinion of the Investigator, increases the safety risks of participating in the study
  • Subject has a lethal or potentially lethal condition other than IS, with a significant risk of death before 18 months of age such as non-ketotic hyperglycinemia
  • Body weight is below 4 kg
  • Known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias

Part C:

  • Subject experienced any acute tolerability issues in either treatment cycle in Part A which the investigator and the sponsor medical monitor consider a risk for further participation
  • Subject met any withdrawal criteria in Part A
  • Subject has experienced any adverse effects or developed any new medical conditions since enrollment in Part A which the investigator considers could significantly increase the safety risks of participating in Part C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02829827


Locations
Layout table for location information
France
Ep0078 401
Paris, France
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
Investigators
Layout table for investigator information
Study Director: UCB Cares +1 8445992273 (UCB)

Layout table for additonal information
Responsible Party: UCB Biopharma S.P.R.L.
ClinicalTrials.gov Identifier: NCT02829827     History of Changes
Other Study ID Numbers: EP0078
2016-002107-26 ( EudraCT Number )
First Posted: July 12, 2016    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
Radiprodil
Infantile spasms
IS
Infantile
Spasms
Epilepsy
Paediatrics
Drug-resistant
West Syndrome
Hypsarrhythmia
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Cramp
Spasm
Spasms, Infantile
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Epilepsy, Generalized
Epilepsy
Brain Diseases
Central Nervous System Diseases
Epileptic Syndromes